Biostage, Inc. Common Stock
BSTG
BSTG was delisted on the 5th of October, 2017.
26 hedge funds and large institutions have $2.23M invested in Biostage, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 5 closing their positions.
10% less funds holding
Funds holding: 29 → 26 (-3)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
32% less capital invested
Capital invested by funds: $3.27M → $2.23M (-$1.04M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$33.3K |
| 2 |
WIC
Woodmont Investment Counsel
Nashville,
Tennessee
|
+$10.8K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.69K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$5.92K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$4.25K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$740K |
| 2 |
Renaissance Technologies
New York
|
-$73K |
| 3 |
PM
Penbrook Management
New York
|
-$49.5K |
| 4 |
TSP
Tappan Street Partners
Chicago,
Illinois
|
-$37.7K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$30K |
BSTG Hedge Fund Activity: Q3 2016 in Review
26 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Biostage, Inc. Common Stock (BSTG) for Q3 2016, worth a combined $2.23M — down 32% from $3.27M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of BSTG and 2 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 5 added.
The largest buyer was Panagora Asset Management, opening a new position worth an estimated $33.3K. The largest seller was Anson Funds Management, exiting entirely with an estimated $740K sold.
- 26 institutional investors held Biostage, Inc. Common Stock (BSTG) as of Q3 2016, down from 29 in Q2 2016.
- Funds reported $2.23M of Biostage, Inc. Common Stock stock for Q3 2016, down 32% quarter-over-quarter.
- 2 funds opened new Biostage, Inc. Common Stock positions in Q3 2016 and 5 closed out, a net change of -3 holders.
- The largest Biostage, Inc. Common Stock buyer in Q3 2016 was Panagora Asset Management, an estimated $33.3K added.
- The largest Biostage, Inc. Common Stock seller in Q3 2016 was Anson Funds Management, an estimated $740K sold.
Based on aggregated 13F filings for Q3 2016.